Medication Administration Routes Nursing Guide 2026: Technique, Onset, and Nursing Considerations

Route Comparison: Onset and Bioavailability

Intravenous (IV) Administration

Intravenous administration delivers medication directly into the bloodstream, bypassing all absorption barriers and achieving 100% bioavailability. Onset is immediate — making IV the route of choice for emergencies (cardiac arrest medications, anaphylaxis, seizures, hypertensive emergencies) and for drugs requiring precise pharmacokinetic control.

IV push (IVP): Medication delivered via syringe directly into a saline lock or IV port over a specified time (e.g., "push over 2 minutes"). Rate matters — medications pushed too rapidly can cause phlebitis, pain at the site, or systemic toxicity (hypotension from morphine push, arrhythmia from adenosine if given too slowly, cardiac arrest from potassium if pushed). Always verify the push rate for any IV push medication.

Intermittent infusion (IVPB): The medication is diluted in a small-volume bag (typically 50–250 mL) and infused over a set time (usually 15–60 minutes). Used for antibiotics, antiemetics, and electrolyte replacement. Compatibility with the primary infusion must be verified — some medications precipitate or deactivate each other when mixed.

Continuous infusion: Medications requiring sustained plasma concentrations (vasopressors, insulin, heparin, sedatives, analgesics) are administered as continuous infusions titrated to clinical effect. Rate is typically expressed as mL/hr or mcg/kg/min for weight-based medications.

Intramuscular (IM) Administration

Intramuscular injections deliver medication into muscle tissue, where absorption occurs via the capillary network. IM injections are used for medications that would irritate subcutaneous tissue, require faster absorption than oral administration provides, or cannot be given IV (many vaccines, depot formulations).

IM injection sites and volume limits:

Z-track technique: Recommended for all IM injections to minimize leakage of medication along the needle track into subcutaneous tissue (which causes pain and irritation). Pull the skin laterally 1–1.5 inches with the non-dominant hand, inject perpendicular to the skin, hold for 10 seconds, withdraw the needle, and release the skin simultaneously. Do not massage after injection — massage increases medication leakage into the subcutaneous space.

Subcutaneous (SubQ) Administration

Subcutaneous injections are delivered into the fatty tissue layer beneath the dermis but above the muscle. Absorption is slower than IM due to less vascular supply in adipose tissue — this slower, more sustained absorption makes SubQ ideal for medications requiring gradual systemic release (insulin, heparin, enoxaparin, certain opioids).

SubQ sites: Abdomen (preferred — most consistent absorption; avoid 2-inch radius around navel), outer thigh, outer upper arm. Rotate injection sites within the selected region to prevent lipodystrophy (abnormal fat distribution from repeated injections at the same site) — lipodystrophy causes unpredictable insulin absorption and should be specifically assessed in patients on long-term SubQ insulin.

Needle selection: 25–27 gauge, 5/8-inch needle for most SubQ injections. Angle 45–90 degrees depending on patient body habitus (thin patients require 45° to avoid hitting muscle; obese patients tolerate 90°). Volume limit: typically 1 mL maximum per SubQ injection.

Aspiration policy: Current evidence and CDC guidance do not recommend aspiration before SubQ injections — there are no large blood vessels in standard SubQ sites, and aspiration changes the medication's pH and can activate some formulations (like insulin detemir).

Oral (PO) Administration

Oral medication is the safest, most convenient, and most cost-effective route for stable patients. Medication is absorbed primarily in the small intestine, passes through the portal circulation, and undergoes "first-pass metabolism" in the liver before reaching systemic circulation — substantially reducing the effective dose of some medications relative to IV equivalents.

First-pass effect: Drugs with significant first-pass hepatic metabolism (morphine, nitroglycerin, propranolol, lidocaine) have much lower oral bioavailability than their IV equivalents. The oral morphine: IV morphine equianalgesic ratio is approximately 3:1 because of first-pass metabolism — 30 mg of oral morphine is roughly equivalent to 10 mg IV morphine.

Crushing considerations: Not all tablets can be crushed. Extended-release (XL, XR, ER, SR) formulations must NEVER be crushed — crushing destroys the controlled-release mechanism and delivers the entire dose at once (dose-dumping). Enteric-coated tablets must not be crushed. Consult an approved "do not crush" list before crushing any tablet for nasogastric tube administration.

Sublingual (SL) Administration

The sublingual mucosa is highly vascular and thin, allowing rapid drug absorption directly into the systemic circulation — bypassing first-pass hepatic metabolism. This makes SL ideal for drugs that are extensively metabolized by the liver on oral administration (nitroglycerin) or drugs requiring rapid onset.

Common SL medications: Nitroglycerin (onset 1–3 minutes; used for acute angina); buprenorphine (Suboxone — absorbed SL; swallowing inactivates it via first-pass metabolism); lorazepam (in some formulations); desmopressin. Instruct patients to place the tablet or spray under the tongue and NOT to swallow, eat, or drink until the medication dissolves — swallowing transfers the medication to the GI tract and eliminates the sublingual benefit.

Inhaled Medications: MDI and Nebulizer

Metered-dose inhaler (MDI) technique: Shake the inhaler, hold upright, exhale fully, seal lips around the mouthpiece, press the inhaler as you begin a slow deep inhalation, inhale fully over 3–5 seconds, hold breath for 10 seconds, wait 1 minute between puffs. A spacer device improves medication delivery to the lungs for patients with poor coordination — spacers are particularly important for corticosteroid MDIs (reduces oropharyngeal deposition and candida risk).

Nebulizer: Converts liquid medication into an aerosol mist for inhalation — used when the patient cannot coordinate MDI use (altered mental status, severe distress, very young or very old patients). Used in acute asthma and COPD exacerbations (albuterol, ipratropium). Requires approximately 5–15 minutes of treatment time.

Sequence matters: When multiple inhaled medications are prescribed, administer bronchodilators first (albuterol), then ipratropium, then inhaled corticosteroids. The bronchodilator opens airways first, allowing better penetration of subsequent medications.

Related guides: Medical abbreviations | Dosage calculations | IV complications | NG tube guide